Novo Nordisk's recent financial results and clinical progress haven't impressed Wall Street. Investors looking to strike ...

Some health experts view GLP-1s as a promising option for PCOS, which lacks a standard treatment and affects millions of ...

As the global obesity medication market skyrockets, South Korean pharmaceuticals are rushing to develop national obesity ...

Ozempic, a drug known for its physical health benefits, is now gaining recognition for its effectiveness in treating ...

Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Hims & Hers Health, Inc. (NYSE: HIMS) and certain of the Company's senior executives for ...

The law firm of Kessler Topaz Meltzer & Check, LLP ( informs investors that securities class action lawsuits have been fil ...

A study reveals potentially fatal side effects of GLP-1 drugs, that people are using to lose weight. It’s well known that ...

Novo Nordisk sees solid Q1 results, major GLP-1 growth potential, and limited downside despite guidance cut and rising risks.